Navigation Links
UT MD Anderson, Texas A&M team up to treat canine lymphoma
Date:2/7/2012

A new immunotherapy for companion dogs with advanced-stage non-Hodgkin lymphoma (NHL) has been shown to improve survival while maintaining quality of life, according to a study published in the journal Scientific Reports. The study resulted from a collaboration between The University of Texas MD Anderson Children's Cancer Hospital in Houston and Texas A&M University College of Veterinary Medicine in College Station.

Using a T-cell therapy developed at MD Anderson Children's Cancer Hospital, veterinarians from Texas A&M saw a nearly four-fold improvement in tumor-free survival compared to dogs who received only chemotherapy. The median tumor-free survival for the Texas-based dogs increased by close to nine months, which is roughly equivalent to seven years in a human life span.

NHL is one of the most common cancers in dogs, according to Texas A&M veterinarians. Although standard chemotherapy can achieve remission, it is rarely a curative treatment, with the two-year survival rate remaining less than 20 percent. When investigators from MD Anderson and Texas A&M met, they explored the feasibility of administering T cells to improve survival.

"We followed the same rigid standards that we practice for human clinical trials at MD Anderson to ensure the safety of each dog," said Laurence Cooper, M.D., Ph.D., professor and section chief of cell therapy at the children's hospital and senior investigator on the study. "While these pets are benefiting from the T-cell infusions, this collaboration with Texas A&M is a driving force for undertaking similar clinical trials in humans."

To accomplish the T-cell therapy, researchers took a sample of peripheral blood from each dog entering the study. Then the T cells were separated and expanded in Cooper's laboratory over several weeks. As the T cells grew at MD Anderson, the canines received a chemotherapy regimen at Texas A&M similar to what humans with NHL receive, a combination of cyclophosphamide, vincristine, doxorubicin and prednisone. The T cells were then given back intravenously after the chemotherapy to improve the anti-tumor effects.

"The therapy was well tolerated in all dogs who received the infusions. We saw fewer side effects than with traditional chemotherapy, and the pet owners were please with how their dogs tolerated the protocol," said Heather Wilson-Robles, DVM, DACVIM(Oncology), assistant professor at Texas A&M. "The owners were also very pleased to be supporting research that may further enhance cancer therapy in humans and pets with cancer."

"Treating dogs with cancer provides us with a great comparative oncology model for humans," said Colleen O'Connor, Ph.D., post-doctoral fellow at MD Anderson and one of the primary investigators on the study. "We learned important details about the interaction between chemotherapy and tumor cells that can be harnessed to improve the body's immune response. This is something we hadn't appreciated thus far from our clinical research in humans."

From the trial, investigators found that:

  • Chemotherapy, while damaging the canine tumor, also makes the tumor cells susceptible to recognition by the infused T cells
  • Infusing back the patient's T cells after chemotherapy can work to improve the survival of canines with NHL, since these T cells were held outside the body preventing damage from the chemotherapy
  • Biomarkers were identified that can potentially play a role in determining prognosis

Overall the study further affirmed the ability to use the body's own immune cells, such as T cells, to fight cancer. As a result, MD Anderson and Texas A&M collaborators are creating a program focusing on harvesting and expanding T cells at a large scale for broad clinical use.

Investigators at both institutions are working to open a new trial that will infuse genetically modified T cells that are tumor specific and potentially even more effective against the canine cancer cells.


'/>"/>

Contact: Sara Farris
sfarris@mdanderson.org
713-792-9133
University of Texas M. D. Anderson Cancer Center
Source:Eurekalert

Related medicine news :

1. Research finds Medicare and private insurance spending similar throughout Texas
2. Scott & White Healthcare is 1 of 3 in Texas to receive workforce development grants
3. TB Outbreaks in Texas Schools Show Disease Still a Threat
4. 2 scientists at the University of Texas at Austin receive early career awards from White House
5. Internationally recognized BME professor to join University of Texas as visiting scholar
6. Drug recognition program available for Texas employers
7. Bad cholesterol not as bad as people think, shows Texas A&M study
8. Largest physics meeting of the year: March 20-25, 2011, Dallas, Texas
9. Wild Hogs in Texas Pose Infection Risk to Humans
10. Texas Center for Cancer Nanomedicine targets 2 tough cancers
11. Health IT program at the University of Texas at Austin receives $2.7 million in federal funding
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... Texas (PRWEB) , ... January 24, 2017 , ... ... year introduces more changes during the Annual Enrollment Period (AEP) and the Open ... scrambling looking for health insurance coverage. Mainly, people are witnessing higher deductibles, rising ...
(Date:1/24/2017)... ... 2017 , ... Manzo Pharmaceuticals, LLC., announced that the name ... the United States Patent and Trademark Office. The purpose of this is ... thinking that other products are similar to the patented Lacto-Freedom Probiotic. ...
(Date:1/24/2017)... ... January 24, 2017 , ... Seceon , ... threats in real-time, today announced a strategic partnership with Paramount , the ... respond and protect their critical information assets and infrastructure, in a comprehensive and ...
(Date:1/24/2017)... , ... January 24, 2017 , ... Bellus Medical, a ... team of medical experts. In his new role Dr. Dobke will provide physician oversight ... Dr. Dobke is the Head of Plastic Surgery and Associate Professor of Surgery at ...
(Date:1/24/2017)... ... , ... The University of Iowa, long recognized as one of the top ... provides teachers with the specific skills and training they need to teach English as ... students and HigherEducation.com is working to ensure that this new program is available to ...
Breaking Medicine News(10 mins):
(Date:1/24/2017)... India , Jan. 24, 2017 Market Research Future ... Integumentary System Market. The global market for Plastic Surgery & Integumentary ... by the end of the forecasted period. Market Highlights ... Global Plastic Surgery ... market and predicted that the market will reach high growth figures ...
(Date:1/24/2017)... , Jan. 24, 2017 Regeneron Pharmaceuticals, Inc. ... Public today recognized 40 finalists in the Regeneron Science ... and math competition for high school seniors. Finalists were ... of their research projects. The finalists will ... from March 9-15 to undergo a rigorous judging process ...
(Date:1/24/2017)... LONDON , January 24, 2017 Analysis ... End User Liquid Biopsies - our new study reveals ... biopsy market heading? If you are involved in this sector you ... you the potential revenues streams to 2027, assessing data, trends, opportunities ... ...
Breaking Medicine Technology: